Márk László, Erdej Ferenc, Dani Gyözö, Borbély Marianna, Sziklai György, Nagy Erzsébet, Hajdara Ildikó, Katona András
Békés Megyei Képviseló-testület Pándy Kálmán Kórháza, II. Belgyógyászat-Kardiológia, Gyula.
Orv Hetil. 2004 May 9;145(19):1001-6.
The atrial fibrillation is a severe and frequent disease, which influences greatly the patients' quality of life. Only a few Hungarian studies exist which discuss the physicians' own experiences in its treatment.
The description of the experiences acquired in an internal medicine department with cardiological profile during the treatment based on the actual guidelines and the review of the results of one year follow-up.
Retrospective analysis of the data of patients treated with atrial fibrillation between 1 january 1999 and 31 december 2001 and a one year follow-up was performed. The age, gender, success in cardioversion, the antiarrhythmic therapy at the discharge and the modification in it during the first year were evaluated.
During the 3 years long period 1115 patients with atrial fibrillation were admitted (53.9% female, 46.1% male, the mean age was 72.0 +/- 10.4 years), 391 of whom were discharged with sinus rhythm. In 193 cases (49%) a spontaneous cardioversion was observed. 120 electrical (31%) and 78 pharmacological (20%) cardioversions were performed. The electrical form was carried out in 42 cases with acute atrial fibrillation (in 36 of them successfully) and in 100 cases as an elective procedure, in 84 successfully. Pharmacological cardioversion was made in 39 acute cases with the administration of propafenone (in 29 ones successfully) and in 57 elective cases with quinidine + beta-blocker + magnesium (in 49 ones successfully). For the maintenance of sinus rhythm in the 38.8% of cases amiodarone, 24.0% propafenone, 19.9% sotalol, 10.7% beta-blocker, 0.8% quinidine, 0.5% prajmaline was administered, and 5.1% of the patients didn't receive any special treatment. During the one year follow-up from the 391 patients 261 remained on sinus rhythm, in 81 cases (21%) the return of the atrial fibrillation was diagnosed (in 57 of them a successful cardioversion was performed again), 11 patients (3%) died and 38 (9%) were lost for observation. At the time of the one year control 57.8% of patients treated with amiodarone, 61.7% of those treated with propafenone, 67.9% with sotalol and 35.7% with beta-blocker remained on sinus rhythm. The amiodarone was omitted in 17 cases because of its side effects.
The treatment of the atrial fibrillation has to be performed individually taking into account the guidelines, the comorbidity, the time of the beginning of rhythm disorder, the patients' present other drugs and the former antiarrhythmic therapy. A continuous and consistent follow-up of these patients is crucial.
心房颤动是一种严重且常见的疾病,对患者的生活质量有很大影响。匈牙利仅有少数研究探讨了医生在其治疗中的自身经验。
描述内科心脏病学专业科室依据实际指南进行治疗所获得的经验,并回顾一年随访结果。
对1999年1月1日至2001年12月31日期间接受心房颤动治疗的患者数据进行回顾性分析,并进行一年随访。评估了患者的年龄、性别、复律成功率、出院时的抗心律失常治疗以及第一年中的治疗调整情况。
在这3年期间,共收治1115例心房颤动患者(女性占53.9%,男性占46.1%,平均年龄为72.0±10.4岁),其中391例出院时为窦性心律。193例(49%)观察到自发复律。进行了120次电复律(31%)和78次药物复律(20%)。电复律在42例急性心房颤动患者中进行(其中36例成功),作为择期手术在100例患者中进行,84例成功。药物复律在39例急性病例中使用普罗帕酮进行(其中29例成功),在57例择期病例中使用奎尼丁+β受体阻滞剂+镁进行(其中49例成功)。为维持窦性心律,38.8%的病例使用胺碘酮,24.0%使用普罗帕酮,19.9%使用索他洛尔,10.7%使用β受体阻滞剂,0.8%使用奎尼丁,0.5%使用普拉马林,5.1%的患者未接受任何特殊治疗。在对391例患者进行的一年随访中,261例维持窦性心律,81例(21%)被诊断为心房颤动复发(其中57例再次成功复律),11例(3%)死亡,38例(9%)失访。在一年复查时,使用胺碘酮治疗的患者中57.8%维持窦性心律,使用普罗帕酮治疗的患者中61.7%维持窦性心律,使用索他洛尔治疗的患者中67.9%维持窦性心律,使用β受体阻滞剂治疗的患者中35.7%维持窦性心律。17例因胺碘酮的副作用而停用。
心房颤动的治疗必须根据指南、合并症、心律失常开始时间、患者目前正在使用的其他药物以及既往抗心律失常治疗情况进行个体化治疗。对这些患者进行持续、一致的随访至关重要。